文献速递消化道肿瘤放疗放疗物理与技术

胰腺癌患者来源类器官的放射反应评估

Radiation response assessment of organoids derived from patients with pancreatic cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-07-27

本研究探讨胰腺癌患者来源类器官(PDO)能否模拟放疗反应及是否存在剂量-反应关系,对来自两名胰腺癌患者的PDO(HUB-08-B2-022A和HUB-08-B2-026B)给予0至40 Gy照射,第7天和第10天检测ATP水平评估活力。结果两种PDO均显示照射剂量-反应相关性,初步提示胰腺癌PDO适合体外评估放射反应,需进一步实验以最终模拟个体化治疗反应。

要点

  • 两种胰腺癌PDO在10天读数下均显示剂量-反应关系,HUB-08-B2-022A较HUB-08-B2-026B更敏感。
  • 7天读数下两种PDO在最高12 Gy时活力均高于50%(rAUC分别为0.79和0.69)。
  • 剂量增至40 Gy未进一步影响活力,但剂量-反应关系仍存在(rAUC分别为0.13和0.26)。

核心结论

  • 在本实验设置下,两种胰腺癌PDO均显示照射剂量-反应相关性。
  • 这些初步发现提示胰腺癌PDO适合体外评估放射反应。
  • 需进一步实验以最终模拟个体化治疗策略的治疗反应。

研究设计与样本

  • 本研究为体外研究,使用来自两名胰腺癌患者(HUB-08-B2-022A和HUB-08-B2-026B)的PDO。
  • PDO接受0至40 Gy剂量照射,于第7天和第10天通过检测ATP水平评估活力。
  • 结果归一化:0 Gy时活力定义为100%,绝对活力0定义为0%;计算相对曲线下面积(rAUC,0=完全敏感,1=完全抵抗)。

主要发现

  • 7天读数下,HUB-08-B2-022A和HUB-08-B2-026B在最高剂量12 Gy时活力均高于50%(rAUC分别为0.79和0.69)。
  • 10天读数下,两种PDO均显示剂量-反应关系,HUB-08-B2-022A较HUB-08-B2-026B更敏感(rAUC分别为0.37和0.51)。
  • 剂量增至40 Gy未进一步影响活力,但剂量-反应关系仍存在(rAUC分别为0.13和0.26)。
  • 最终实验(10天读数、最大剂量14 Gy)中,两种PDO的剂量-反应相关性均显著(rAUC分别为0.28和0.45),HUB-08-B2-022A最敏感。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出这些为初步发现,需进一步实验以最终模拟个体化治疗策略的治疗反应。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effectiveness of radiotherapy for pancreatic cancer is debated. Patient-derived organoids (PDOs) already mimicked clinical radiation response in other cancer types, which could be valuable in pancreatic cancer as well. This study aimed to investigate whether PDOs can be used to model RT response in pancreatic cancer and to explore the presence of a dose-response correlation. METHODS: PDOs derived from two pancreatic cancer patients (HUB-08-B2-022A and HUB-08-B2-026B) were irradiated with doses ranging from 0 to 40 Gray. Viability assessments were conducted after seven and 10 days by measuring ATP-levels. Results were normalized, defining the viability at 0 Gray as 100 % and an absolute viability of 0 as 0 %. The relative area under the curve (rAUC) was calculated (0 = total sensitivity, 1 = total resistance). RESULTS: With a readout time of seven days, both HUB-08-B2-022A and HUB-08-B2-026B exhibited viability above 50 % at the highest dose of 12 Gy (rAUC of 0.79 and 0.69, respectively). With a readout time of 10 days, both PDOs showed a dose-response relation although HUB-08-B2-022A was more sensitive than HUB-08-B2-026B (rAUC of 0.37 and 0.51, respectively). Increasing the radiation dose to 40 Gy did not further affect viability, but the dose-response relation remained present (rAUC of 0.13 and 0.26, respectively). In the final experiment with a readout time of 10 days and a maximum dose of 14 Gy, the dose-response correlation was paramount in both PDOs (rAUC 0.28 and 0.45, respectively), with HUB-08-B2-022A being most sensitive. CONCLUSIONS: In this setup, both pancreatic cancer PDOs showed an irradiation dose-response correlation. These preliminary findings suggest that pancreatic cancer PDOs are suitable for assessing radiation response in vitro. Further experiments are needed to eventually simulate treatment responses to personalized treatment strategies.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. van Goor IWJM, Raymakers L, Andel DSH, et al. Radiation response assessment of organoids derived from patients with pancreatic cancer. Clin Transl Radiat Oncol. 2024. PMID: 39192878. doi:10.1016/j.ctro.2024.100829

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。